Trubion reports positive data from Phase 2B TRU-015 study

Business of Biotech

Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.

Trubion’s President and CEO, Dr. Peter A. Thompson, will be a panelist at BIO Investor Forum’s “Resisting the Enemy Within – Keeping Score on the War Against Autoimmune Disease” Therapeutic Workshop.

Business of Biotech  |  Email This Post  |  Printer Friendly
Tags: ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>